<DOC>
	<DOC>NCT00818324</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients</brief_summary>
	<brief_title>Long Term Administration Study of OPC-12759 Ophthalmic Suspension</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>1. Out patient; 2. Ocular discomfort severity is moderate to severe; 3. Cornealconjunctival damage is moderate to severe; 4. Unanesthetized Schirmer's test score of 5mm/5minutes or less,or tear breakup time is 5 seconds or less; 5. Best corrected visual acuity of 0.2 or better in both eyes. 1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis scicca; 2. Ocular hypertention patient or glaucoma patient with ophthalmic solution; 3. Anticipated use of any topicallyinstilled ocular medications or patients who cannot discontinue the use during the study; 4. Anticipated use of contact lens during the study; 5. Patient with punctal plug; 6. Any history of ocular surgery within 12 months; 7. Female patients who are pregnant, possibly pregnant or breast feeding; 8. Known hypersensitivity to any component of the study drug or procedual medications; 9. Receipt of any investigational product within 4 months.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>